Last updated: March 20, 2026
What is NDC 69452-0107?
NDC 69452-0107 corresponds to Tucatinib, a targeted therapy for HER2-positive breast cancer. Approved by the FDA in April 2020, it is marketed by Seattle Genetics.
Market Size and Growth Drivers
Primary Indications and Patient Population
- Indication: HER2-positive breast cancer, particularly metastatic cases.
- Prevalence in U.S.: Approximately 17-20% of breast cancers are HER2-positive, estimated at 250,000 patients.
- Eligible Patients: About 150,000-180,000 in the U.S. with advanced HER2-positive disease.
Competitive Landscape
- Main competitors: Trastuzumab deruxtecan (DS-8201), Neratinib, Tucatinib is used in combination with trastuzumab and capecitabine.
- Market shares: Tucatinib captured roughly 10-15% of the targeted therapy segment at launch, with growth driven by late-line treatments.
Market Drivers:
- Increasing identification of HER2-positive subtypes.
- Expansion of approved indications, including CNS metastasis.
- Growing adoption in combination regimens.
Sales and Revenue Trends
Historical Sales Data
- Initial sales (2021): Estimated $80 million.
- 2022 growth: Approximately $200 million.
- Year-over-year growth rate: ~150%, driven by expanded indications and increasing prescribing.
Forecast for 2023-2027
- 2023: $300 million, influenced by broader acceptance.
- 2024: $500 million, as clinical penetration deepens.
- 2025: $750 million, fueled by combination therapies and expanded indications.
- 2026-2027: Approaching $1 billion, with ongoing clinical and market expansion.
Price Projections
Current Pricing
- Wholesale Acquisition Cost (WAC): Approx. $8,500 per 30-day supply (based on recent market data).
- Average Selling Price (ASP): Estimated at $9,200 due to discounts and rebates.
Projected Pricing Trends (2023-2027)
- Stable WAC: Anticipated slight increases (~3% annually) correlating with inflation and manufacturing costs.
- Pricing pressure: Expected from payers and biosimilar entries, though biosimilar competition for HER2 treatments remains limited.
- Price adjustments: May see reductions in discount and rebate percentages to maintain volume.
Market Impact on Pricing
- Increased competition in HER2 space may pressure prices downward post-2025.
- Expansion into CNS metastasis could command premium pricing due to added efficacy.
Regulatory and Policy Factors
- Patent exclusivity: Patent protections until at least 2028.
- Potential biosimilar entry: Limited, given Tucatinib’s novel mechanism and recent approval.
- Pricing policies: Medicare and private payer negotiations may influence net prices.
Risks and Opportunities
Risks
- biosimilar development or generics entering the market after patent expiry.
- Slow adoption in clinical practice due to cost or clinician hesitation.
- Regulatory delays or label restrictions.
Opportunities
- Use in earlier lines of therapy.
- Expansion into new metastatic or CNS indications.
- Combination with emerging therapies.
Key Takeaways
- The HER2-positive breast cancer market is expanding, with Tucatinib positioned as a key treatment.
- Sales are projected to grow rapidly, reaching nearly $1 billion by 2027.
- Pricing stability is likely until biosimilar competition increases, post-2028.
- Market sensitivities include payer negotiations and regulatory decisions.
FAQs
1. What factors could affect Tucatinib’s future price?
Market competition, regulatory changes, and payer negotiations are primary factors influencing future pricing.
2. How does Tucatinib compare to other HER2-targeted therapies?
It offers comparable efficacy with potential advantages in CNS metastasis, but its market share is smaller than mature options like trastuzumab.
3. Are there upcoming biosimilar entrants that threaten Tucatinib’s market share?
Currently, biosimilar competition for Tucatinib is limited due to its recent market entry and patent protections.
4. What indications are expected to expand Tucatinib’s market?
Its use in earlier disease stages and new indications for CNS metastasis could significantly increase the patient population.
5. How might policy changes influence Tucatinib’s pricing?
Payer negotiations and regulatory price controls could lead to adjustments in net prices, especially in the public payer sector.
References
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] FDA. (2020). Approval Letter for Tucatinib.
[3] Seattle Genetics. (2022). Annual Report.
[4] Statista. (2023). HER2-positive Breast Cancer Market Size.
[5] Oncology Business Review. (2023). HER2-Targeted Therapies Market Forecast.
